tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KYTX Stock Latest News

Kyverna Therapeutics Secures $150 Million Loan Facility
Company AnnouncementsKyverna Therapeutics Secures $150 Million Loan Facility
6d ago
8K
KYTX
Kyverna Therapeutics secures up to $150M in non-dilutive financing
PremiumThe Fly
Kyverna Therapeutics secures up to $150M in non-dilutive financing
6d ago
KYTX
3 Best Stocks to Buy Now, 10/30/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 10/30/2025, According to Top Analysts
10d ago
KYTX
OPRA
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101
PremiumRatings
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101
10d ago
KYTX
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
PremiumThe Fly
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
10d ago
KYTX
Kyverna Therapeutics’ KYV-101 Shows Promising Phase II Results in gMG, Supporting Buy Rating
PremiumRatingsKyverna Therapeutics’ KYV-101 Shows Promising Phase II Results in gMG, Supporting Buy Rating
11d ago
KYTX
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
Premium
The Fly
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
11d ago
KYTX
Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
Premium
Company Announcements
Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
11d ago
8K
KYTX
Kyverna Therapeutics Reports Positive Phase 2 Trial Results
PremiumCompany Announcements
Kyverna Therapeutics Reports Positive Phase 2 Trial Results
11d ago
8K
KYTX
Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial
PremiumThe Fly
Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial
11d ago
KYTX
Kyverna Therapeutics Advances CAR T-Cell Therapy Study for Myasthenia Gravis
PremiumCompany Announcements
Kyverna Therapeutics Advances CAR T-Cell Therapy Study for Myasthenia Gravis
13d ago
KYTX
Kyverna Therapeutics Advances with Promising CAR-T Therapy for Stiff Person Syndrome
PremiumCompany Announcements
Kyverna Therapeutics Advances with Promising CAR-T Therapy for Stiff Person Syndrome
13d ago
KYTX
Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy
PremiumCompany AnnouncementsKyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy
13d ago
KYTX
Kyverna Therapeutics’ Promising Clinical Data and Market Potential Justify Buy Rating
Premium
Ratings
Kyverna Therapeutics’ Promising Clinical Data and Market Potential Justify Buy Rating
13d ago
KYTX
Mitchell Kapoor’s Buy Rating on Kyverna Therapeutics Driven by Increased Confidence in KYV-101 for Myasthenia Gravis and Raised Approval Probability
Premium
Ratings
Mitchell Kapoor’s Buy Rating on Kyverna Therapeutics Driven by Increased Confidence in KYV-101 for Myasthenia Gravis and Raised Approval Probability
13d ago
KYTX
Kyverna Therapeutics price target raised to $20 from $10 at H.C. Wainwright
PremiumThe Fly
Kyverna Therapeutics price target raised to $20 from $10 at H.C. Wainwright
13d ago
KYTX
Kyverna Therapeutics price target raised to $27 from $24 at Wells Fargo
PremiumThe Fly
Kyverna Therapeutics price target raised to $27 from $24 at Wells Fargo
1M ago
KYTX
PremiumCompany Announcements
Kyverna Therapeutics Announces Board Member Resignation
1M ago
8K
KYTX
PremiumRatings
Kyverna Therapeutics: Promising Potential in MS and MG with Strong Financials and Conservative Valuation
1M ago
KYTX
PremiumRatingsKyverna Therapeutics’ KYV-101: Promising Efficacy and Safety in Multiple Sclerosis and Beyond
1M ago
KYTX
Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101
Premium
The Fly
Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101
2M ago
KYTX
Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM
Premium
The Fly
Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM
2M ago
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >